Genprex【GNPX】株式ニュース

名称	銘柄コード	市場	種別
Genprex Inc	GNPX	NASDAQ	普通株式

	前日比	前日比 %	現在値	時刻
	-0.03	-1.44%	2.05	07:00:05

始値	安値	高値	終値	前日終値
2.03	2.01	2.08	2.05	2.08

この銘柄の詳細情報 »

最新ニュース

日付	時間	ソース	タイトル
2024/5/30	21:31	PRNUS	Genprex to Present at the 2024 BIO International Convention
2024/5/21	05:35	EDGAR2	Form 424B5 - Prospectus [Rule 424(b)(5)]
2024/5/16	05:15	EDGAR2	Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/5/14	21:31	PRNUS	Genprex Doses First Patient in Acclaim-3 Clinical Study of..
2024/5/13	21:31	PRNUS	Genprex Announces the Appointment of Jose A. Moreno Toscano..
2024/5/09	21:11	EDGAR2	Form 8-K - Current report
2024/5/09	07:08	PRNUS	Genprex Announces the Passing of its Co-Founder and Chief..
2024/5/01	21:31	PRNUS	Genprex to Present and Participate at Upcoming May Investor..
2024/4/09	21:31	PRNUS	Genprex Collaborators Report Positive Preclinical Data on..
2024/4/03	21:31	PRNUS	Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical..
2024/4/02	21:31	PRNUS	Genprex Collaborators Publish Positive Preclinical Data with..
2024/3/23	05:10	PRNUS	Genprex Announces Closing of $6.5 Million Registered Direct..
2024/3/20	02:24	PRNUS	Genprex Announces $6.5 Million Registered Direct Offering..
2024/3/19	21:36	PRNUS	Genprex Announces $6.5 Million Registered Direct Offering..
2024/3/12	22:01	PRNUS	Genprex Receives Notice of Patent Grant for Korean Patent..
2024/3/06	23:18	EDGAR2	Form 8-K - Current report
2024/3/06	22:30	PRNUS	Genprex Collaborators to Present Positive Preclinical Data..
2024/2/26	22:45	EDGAR2	Form 8-K - Current report
2024/2/22	06:34	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
2024/2/22	06:32	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
2024/2/22	06:28	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
2024/2/15	04:14	EDGAR2	Form SC 13G/A - Statement of acquisition of beneficial..
2024/2/07	22:15	PRNUS	Genprex Expands Nonclinical Programs into New Therapeutic..
2024/2/06	21:30	PRNUS	Genprex to Present at Upcoming BIO CEO & Investor Conference
2024/2/05	22:15	EDGAR2	Form 8-K - Current report
2024/2/05	21:30	PRNUS	Genprex Announces First Patient Dosed in Phase 2a Expansion..
2024/2/02	21:30	EDGAR2	Form 8-K - Current report
2024/1/31	23:00	EDGAR2	Form 8-K - Current report
2024/1/31	22:42	PRNUS	Genprex Announces 1-for-40 Reverse Stock Split Effective..
2024/1/06	06:17	EDGAR2	Form 8-K - Current report
2024/1/05	21:00	PRNUS	Genprex Provides Business Update and Outlook for 2024
2023/12/19	06:35	EDGAR2	Form 8-K - Current report
2023/12/14	06:50	EDGAR2	Form 424B5 - Prospectus [Rule 424(b)(5)]
2023/12/14	06:44	EDGAR2	Form 8-K - Current report
2023/11/15	01:31	EDGAR2	Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/11/04	05:19	EDGAR2	Form DEFA14A - Additional definitive proxy soliciting..
2023/11/04	05:16	EDGAR2	Form DEF 14A - Other definitive proxy statements
2023/11/01	20:30	PRNUS	Genprex to Present at BIO-Europe 2023 Conference
2023/10/24	06:01	EDGAR2	Form PRE 14A - Other preliminary proxy statements
2023/10/24	05:44	EDGAR2	Form 8-K - Current report
2023/10/20	20:30	PRNUS	Genprex to Host a Virtual Key Opinion Leader Event on..
2023/10/05	01:00	PRNUS	Genprex to Present Data on the Use of REQORSA® for the..
2023/9/26	05:20	EDGAR2	Form 8-K - Current report
2023/9/21	21:30	GLOBE	Genprex Inc. (NASDAQ: GNPX) Receives Orphan Drug Designation..
2023/9/20	21:45	IHNW	Pathways to Progress: How Orphan Drug Designation Sparks..
2023/9/09	05:20	EDGAR2	Form 8-K - Current report
2023/9/07	20:30	PRNUS	Genprex to Present at Upcoming September Investor Conference
2023/9/02	05:17	EDGAR2	Form 8-K - Current report
2023/8/22	20:30	PRNUS	Genprex Appoints Suzanne Thornton-Jones as Senior Vice..
2023/8/22	06:13	EDGAR2	Form 8-K/A - Current report: [Amend]